Logo image
Evaluating the effect of repetitive transcranial magnetic stimulation on sleep difficulties in children with autism spectrum disorder: a randomized controlled trial
Journal article   Open access   Peer reviewed

Evaluating the effect of repetitive transcranial magnetic stimulation on sleep difficulties in children with autism spectrum disorder: a randomized controlled trial

Uchenna Ezedinma, Scott Burgess, Evan Jones, Jyoti Singh, Andrew Ladhams, Gary Campbell, Shauna Fjaagesund, Piotr Swierkowski, Adewuyi A Adeyinka, Alexandra P Metse, …
Sleep Advances, Vol.6(4), pp.1-14
2025
PMID: 41445722
pdf
zpaf0881.07 MBDownloadView
Published Version (Advanced Access) Open Access CC BY V4.0

Abstract

alpha rhythm repetitive transcranial magnetic stimulation autism spectrum disorder sleep difficulties polysomnography children UniSC Diversity Area - Life Stages UniSC Diversity Area - Disability and Inclusion
Study Objectives Evaluate the effect and safety of alpha rhythm-guided repetitive transcranial magnetic stimulation (α-rTMS) on sleep difficulties in children with autism spectrum disorder (ASD). Methods Twenty children (6–12 years old; 16 males; 4 females) with ASD level 2 were randomly assigned (1:1 ratio) to a treatment group (TG) or a waitlist control group (WLCG) (T1). The TG received ten α-rTMS sessions over two weeks, while the WLCG acted as control for that period (T2). Next, the WLCG received α-rTMS for two weeks (T3). All study participants were followed up at one (T4) and four (T5) months. Sleep difficulties were measured using the Children’s Sleep Habit Questionnaire (CSHQ), Actigraphy, and Polysomnography (PSG). Results Group-by-time interactions indicated that the TG had greater improvements than the WLCG in total CSHQ score (p=.008) and, bedtime resistance (p=.003), sleep onset delay (p=.004), and sleep duration (p=.003) subdomain scores. When the WLCG received the α-rTMS, there were improvements in their sleep-disordered breathing (p=.001), parasomnia (p=.002) and sleep duration (p=.018) subdomain scores, while PSG data showed improved Waking After Sleep Onset (WASO) (p=.014), Sleep efficiency (p=.046), and N2 stage (p=.039). The improved CSHQ scores persisted, with actigraphy data showing significant improvement in WASO at T4 and T5. Side effects of α-rTMS were mild and transient. Conclusions This RCT study presents preliminary evidence on the effect and safety of α-rTMS in improving subjective sleep difficulties in children with ASD, with effects lasting up to four months post-intervention. Further studies using a larger sample size and sham-controlled group are warranted. Clinical Trial Registration The trial was registered on July 11, 2023 within the Australian New Zealand Clinical Trials Registry (ANZCTR) https://www.anzctr.org.au/TrialSearch.aspx with registration number: ACTRN12623000757617.

Details

Metrics

6 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Web Of Science research areas
Clinical Neurology
Neurosciences

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Logo image